NRT Share Price

Open 0.09 Change Price %
High 0.09 1 Day 0.00 0.00
Low 0.09 1 Week 0.00 0.00
Close 0.09 1 Month 0.01 12.50
Volume 91686 1 Year -0.03 -25.00
52 Week High 0.14
52 Week Low 0.08
NRT Important Levels
Resistance 2 0.09
Resistance 1 0.09
Pivot 0.09
Support 1 0.09
Support 2 0.09
ASX Australia Most Active Stocks
AGO 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
TEG 0.05 0.00%
AKK 0.01 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
IMU 0.02 100.00%
IMU 0.02 100.00%
PMQ 0.03 50.00%
ARD 0.03 50.00%
ARD 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
EXG 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
AVD 0.01 -50.00%
SRX 16.00 -37.23%
SRX 16.00 -37.23%
More..

Novogen Ltd (ASX: NRT)

NRT Technical Analysis 4
As on 9th Dec 2016 NRT Share Price closed @ 0.09 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.10 & Sell for SHORT-TERM with Stoploss of 0.09 we also expect STOCK to react on Following IMPORTANT LEVELS.
NRT Target for December
1st Target up-side 0.1
2nd Target up-side 0.1
3rd Target up-side 0.1
1st Target down-side 0.08
2nd Target down-side 0.08
3rd Target down-side 0.08
NRT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.novogen.com
NRT Address
NRT
16 - 20 Edgeworth David Avenue
Level 1
Hornsby, NSW 2077
Australia
Phone: 61 2 9476 0344
Fax: 61 2 9476 0388
NRT Latest News
Interactive Technical Analysis Chart Novogen Ltd ( NRT ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novogen Ltd
NRT Business Profile
Novogen Limited operates as a pharmaceutical drug development company worldwide. It focuses on the development of a family of anti-cancer drugs based on super-benzopyran and stealth drug technologies. The company’s lead drug candidate is CS-6, a mitochondrial electron transfer inhibitor for the treatment of temozolomide-resistant glioblastoma multiforme and late-stage chemo-refractory ovarian cancer. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.